Pseudoephedrine Hydrochloride Tablet, Extended Release
FDA Label NDC 58602-884

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Aurohealth Llc for the product Pseudoephedrine Hydrochloride (NDC 58602-884). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding drug facts, purpose, uses, warnings, ask a doctor before use if you have, when using this product do not exceed recommended dosage, otc - stop use, otc - pregnancy or breast feeding, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Drug Facts

Active ingredient (in each tablet)                                               

Pseudoephedrine Hydrochloride USP 240 mg

Purpose

Nasal decongestant

Uses

  •   temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies
  •   reduces swelling of nasal passages
  •   relieves sinus pressure

Warnings

Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

Ask A Doctor Before Use If You Have

  • heart disease
  • high blood pressure
  • thyroid disease
  • diabetes
  • trouble urinating due to an enlarged prostate gland
  • had obstruction or narrowing of the bowel Rarely, tablets of this kind may cause bowel obstruction (blockage), usually in people with severe narrowing of   the bowel (esophagus, stomach or intestine).

Stop use and ask a doctor if

Otc - Stop Use

  • nervousness, dizziness, or sleeplessness occur
  • symptoms do not improve within 7 days or occur with a fever
  • you experience persistent abdominal pain or vomiting

Otc - Pregnancy Or Breast Feeding

If pregnant or breast-feeding, ask a health professional before use.

Keep Out Of Reach Of Children.

In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Directions

adults and children
12 years and over
  • swallow one whole tablet with water every 24 hours
  • do not exceed one tablet in 24 hours
  • do not divide, crush, chew or dissolve the tablet
  • the tablet does not completely dissolve and may be seen in the stool (this is normal)
children under 12 years
do not use this product in children under 12 years of age

Other Information

  •   store at 20° to 25°C (68° to 77°F).
  •   do not use if the individual blister unit is open or torn
  •   see side panel for lot number and expiration date
  •   FDA approved dissolution test specifications differ from USP.

Inactive Ingredients

black iron oxide, cellulose acetate, colloidal silicon dioxide, dibutyl sebacate, glyceryl mono and dicaprylocaprate, hypromellose, lactose monohydrate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol-part. hydrolyzed, propylene glycol, shellac, sodium lauryl sulfate, stearic acid, talc and titanium dioxide.

Questions or comments?

call 1-855-274-4122 (Monday - Friday 8:30 AM to 5:00 PM EST)


Distributed by:
AUROHEALTH LLC
279 Princeton-Hightstown Road
East Windsor, NJ 08520

Made in India

Code: TS/DRUGS/22/2009

Package Label-Principal Display Panel - 2 X 5 Blister Carton Label

AUROHEALTH

NDC 58602-884-58

#Compare to the active
ingredient in Sudafed® Sinus Congestion 24 Hour.

Pseudoephedrine Hydrochloride
Extended-Release Tablets, USP 240 mg
Nasal Decongestant

MAXIMUM STRENGTH

24
HOUR

• SINUS PRESSURE + CONGESTION
• NON-DROWSY

Actual Size

2 x 5 tablets per blister card

Ppackage Label-principal Display Panel (2 x 5 Blister Carton)

Ppackage Label-principal Display Panel (2 x 5 Blister Carton)



 

* Please review the disclaimer below.